Entecavir Treatment of Chronic Hepatitis D

Kabacam G., ÖNDER F. O., Yakut M., Seven G., Karatayli S. C., Karatayli E., ...Daha Fazla

CLINICAL INFECTIOUS DISEASES, cilt.55, sa.5, ss.645-650, 2012 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 55 Sayı: 5
  • Basım Tarihi: 2012
  • Doi Numarası: 10.1093/cid/cis459
  • Dergi Adı: CLINICAL INFECTIOUS DISEASES
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.645-650
  • Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Hayır

Özet

Background. Hepatitis D virus (HDV) requires hepatitis B surface antigen (HBsAg) to propagate infection and cause disease. Entecavir is a nucleoside analog with potent antiviral efficacy, and in the woodchuck animal model it also decreased hepatitis B virus (HBV) cccDNA and woodchuck surface antigen. The aim of this study was to investigate the efficacy of entecavir in chronic hepatitis D (CHD).